AFP-Maytansine Conjugate – a Novel Targeted Cancer Immunotherapy

August 17, 2021
Press Release

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein platform, today announced that its abstract featuring data from the Company’s investigational therapy, ACT-903, has been selected for presentation at the European Society of Medical Oncology (ESMO) Annual Meeting being held virtually September 16-21, 2021.

Details about the abstract selected for poster publication can be found below:

levitra viola https://carlgans.org/report/anime-essay-topics/7/ https://homemods.org/usc/an-essay-about-abortion/46/ breast cancer essay titles in mla source link cialis secundarios sildenafil precio argentina 2015 follow link http://cappuccino.ucsd.edu/how/ampicillin-walgreens/100/ que efectos hace el cialis pirotska viagra dosage https://equalitymi.org/citrate/cialis-launch/29/ ineedessay com dauererektion wegen viagra vs cialis get link enter comparison levitra viagra enter propecia kopen example startup business plan buspirone and cialis essay hard times dengue virus in pakistan essay go here master thesis offers europe compare between two cities essay get link follow link enter source cialis levels arguably essays by christopher hitchens review Title: AFP-Maytansine Conjugate – a Novel Targeted Cancer Immunotherapy
Abstract Number: 523P
Authors: I. Sherman, R. Boohaker, K. Stinson, P. Griffin, W. Hill
Abstracts are under embargo until 5:00 p.m. ET on Sept. 15, 2021.

For more information about the Annual Meeting, please visit: https://www.esmo.org/meetings/esmo-congress-2021